CG Oncology

CG Oncology CGON Stock

$78.94   -6.888410%
Add to favorites
Market Cap
$7.05B
LOW - HIGH [24H]
$73.00 - $83.97
VOLUME [24H]
$3.16M
P/E Ratio
0
Earnings per share
-$2.76
ISIN
US1569441009
Price   Prediction

CG Oncology Price Chart

Sorry, that's all we've gotfor now...

CG Oncology (CGON) stock price today is 78.94 USD on Tech Market Large (-6.89% on the day). Updated .

CG Oncology CGON Financial and Trading Overview

CG Oncology stock price 78.94 USD
Previous Close 74.4 USD
Open 92 USD
Bid 65.16 USD x 200
Ask 101.95 USD x 200
Day's Range 78.27 - 93.95 USD
52 Week Range 37.01 - 93.95 USD
Volume 9.88M USD
Avg. Volume 999.33K USD
Market Cap 7.57B USD
Beta (5Y Monthly) 0.349
PE Ratio (TTM) N/A
EPS (TTM) -2.76 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 92.15 USD

CGON Valuation Measures

Enterprise Value 6.6B USD
Trailing P/E N/A
Forward P/E -29.456524
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 1228.0989
Price/Book (mrq) 7.6399026
Enterprise Value/Revenue 1069.938
Enterprise Value/EBITDA -25.273

Trading Information

CG Oncology Stock Price History

Beta (5Y Monthly) 0.349
52-Week Change 80.36%
S&P500 52-Week Change 13.32%
52 Week High 93.95 USD
52 Week Low 37.01 USD
50-Day Moving Average 68.04 USD
200-Day Moving Average 66.68 USD

CGON Share Statistics

Avg. Volume (3 month) 999.33K USD
Avg. Daily Volume (10-Days) 1.58M USD
Shares Outstanding 89.32M
Float 68.95M
Short Ratio 10.08
% Held by Insiders 0.91%
% Held by Institutions 113.06%
Shares Short 9.22M
Short % of Float 10.50%
Short % of Shares Outstanding 10.31%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -4293.52%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -18.62%
Return on Equity (ttm) -28.29%

Income Statement

Revenue (ttm) 6.17M USD
Revenue Per Share (ttm) 0.07 USD
Quarterly Revenue Growth (yoy) -3.69%
Gross Profit (ttm) -174026000 USD
EBITDA -261044000 USD
Net Income Avi to Common (ttm) -237458000 USD
Diluted EPS (ttm) -2.76
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 984.46M USD
Total Cash Per Share (mrq) 11.02 USD
Total Debt (mrq) 9.24M USD
Total Debt/Equity (mrq) 0.93 USD
Current Ratio (mrq) 21.703
Book Value Per Share (mrq) 11.097

Cash Flow Statement

Operating Cash Flow (ttm) -187280000 USD
Levered Free Cash Flow (ttm) -119265872 USD

Profile of CG Oncology

Country United States
State TX
City Dallas
Address 3000 Pegasus Park Drive
ZIP 75247
Phone 949 409 3700
Website https://cgoncology.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 142

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Q&A For CG Oncology Stock

What is a current CGON stock price?

CG Oncology CGON stock price today per share is 78.94 USD.

How to purchase CG Oncology stock?

You can buy CGON shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for CG Oncology?

The stock symbol or ticker of CG Oncology is CGON.

Which industry does the CG Oncology company belong to?

The CG Oncology industry is Biotechnology.

How many shares does CG Oncology have in circulation?

The max supply of CG Oncology shares is 89.32M.

What is CG Oncology Price to Earnings Ratio (PE Ratio)?

CG Oncology PE Ratio is now.

What was CG Oncology earnings per share over the trailing 12 months (TTM)?

CG Oncology EPS is -2.76 USD over the trailing 12 months.

Which sector does the CG Oncology company belong to?

The CG Oncology sector is Healthcare.

$2.22T
Total marketcap
$79.85B
Total volume
BTC 58.41%   •   ETH 9.97%
Dominance
Select currency